Navigation Links
Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
Date:8/1/2012

NATICK, Mass., Aug. 1, 2012 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced publication of preclinical models utilizing their proprietary SINE compounds in AML. SINEs specifically and irreversibly inhibit the nuclear transporter exportin 1 (XPO1), more commonly called CRM1 (chromosome region maintenance 1). CRM1 is the exclusive mediator of the nuclear export of p53, p73, pRb, FOXO, p21, p27, BRACA1, and other tumor suppressor proteins, along with the endogenous inhibitor of Nuclear Factor kB (NF-kB) known as IkB. Cancer cells use nuclear export of these key anti-tumor proteins to functionally inactivate them. Blockade of CRM1 with SINE leads to accumulation and activation of tumor suppressor and chemotherapy resistance proteins in the nucleus, leading to selective tumor cell apoptosis while sparing normal cells.

(Logo: http://photos.prnewswire.com/prnh/20120508/NE02031LOGO )

Romero Garzon, MD, PhD, and colleagues at the Ohio State University published a plenary paper in the journal Blood entitled, "Pre-clinical activity of a novel CRM1 inhibitor in acute myeloid leukemia" (PubMed ID: 22677130). The authors showed that Karyopharm's SINE compounds induced apoptosis at nanomolar levels in AML cell lines and in AML blasts from patients. SINEs reduced the levels of the AML oncoprotein FLT3, and when given orally to mice, prolonged their survival with good tolerability.

In the second paper, Tom Look, MD, and colleagues at the Dana Farber Cancer Institute in Boston published a paper in the journal Leukemia entitled "Anti-leukemic activity of nuclear export inhibitors that spare normal hematopoietic cells" (PubMed ID: 22847027). This paper describes the discovery of the SINE compounds based on the X-ray crystal structure of CRM1 using proprietary in silico screening methods developed by Karyopharm's founder, Chief Scientific Officer and head of research and development, Sharon Shacham, PhD, MBA. The authors show that SINEs induce apoptosis at nanomolar levels in multiple different subtypes of AML.  When given orally to mice, SINEs had potent antileukemic effects with negligible toxicity to normal hematopoietic cells, significantly prolonging survival with good tolerability.

Shacham commented, "These publications greatly expand our understanding of the biology of nuclear export and its inhibition by Karyopharm's SINE compounds.  We greatly appreciate the extraordinary partnerships that we have developed with researchers at Ohio State and Dana Farber, particularly as these collaborations have helped us to move into human clinical studies with our novel oral SINE KPT-330."

Together with multiple presentations at the American Association of Cancer Research, American Society of Clinical Oncology, American Society of Hematology, and other meetings, Karyopharm and their academic collaborators have demonstrated the activity of SINEs in diverse hematological and solid tumor malignancies. The recent publications in AML provide a strong rationale for investigating the utility of SINEs in patients with this devastating cancer. 

KPT-330 oral is currently being evaluated in two Phase 1 studies in patients with advanced hematologic and solid tumor malignancies (clinicaltrials.gov: NCT01607892 and NCT01607905).  These studies are being conducted in the United States, Toronto, Canada, and Copenhagen, Denmark. Patients with AML will be eligible to enroll in the advanced hematologic cancer study once the tolerability profile of KPT-330 has been established.

About Karyopharm

Karyopharm is a biopharmaceutical company leading the development of small molecule modulators of nuclear transport. The Company was founded by Drs. Sharon Shacham and Michael Kauffman in late 2008 and has raised approximately $34M since its inception. The Company has won several grants/awards including a Biotech Investment Award by the Multiple Myeloma Research Foundation in 2010. Karyopharm's first program is directed towards the Selective Inhibition of Nuclear Export – its SINE program – targeting CRM1, a major non-redundant nuclear export protein. SINE compounds, including KPT-330 and KPT-335, force the activation of the cell's key tumor suppressor proteins and anti-inflammatory pathways. Karyopharm is currently evaluating two oral SINE compounds in clinical trials. KPT-330 is being evaluated in patients with cancer, and KPT-335 oral is being studied in dogs with relapsed/refractory non-Hodgkin's Lymphomas.  The Company is also evaluating the use of SINEs in autoimmune/inflammatory disorders, viral infections and dermatologic diseases. Karyopharm Therapeutics is located in Natick, Massachusetts.

Contact: Michael Kauffman, mkauffman@karyopharm.com  508-975-4821


'/>"/>
SOURCE Karyopharm Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
2. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 1
3. United Therapeutics Corporation Reports Second Quarter 2012 Financial Results
4. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
5. United Therapeutics Corporation to Announce Second Quarter 2012 Financial Results Before Market Open on Thursday, July 26, 2012
6. Juventas Therapeutics Raises $22.2 Million Series B Financing
7. Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
8. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
9. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
10. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
11. United Therapeutics Announces Additional $100 Million Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
(Date:10/10/2017)... SANTA BARBARA, CALIFORNIA (PRWEB) , ... October 10, ... ... risk management, technological innovation and business process optimization firm for the life sciences ... the BoxWorks conference in San Francisco. , The presentation, “Automating GxP ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... ... a four-tiered line of medical marijuana products targeting the needs of consumers who ... packaging of Kindred takes place in Phoenix, Arizona. , As operators of two ...
(Date:10/6/2017)... Mass. (PRWEB) , ... October 06, 2017 , ... ... female entrepreneurship within the healthcare and technology sector at their fourth annual Conference ... panels featuring 30 inspiring speakers and the ELEVATE pitch competition showcasing early stage ...
Breaking Biology Technology:
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/30/2017)... March 30, 2017 The research team of ... three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae ... realm of speed and accuracy for use in identification, crime investigation, ... cost. ... A research ...
Breaking Biology News(10 mins):